LUNG · Pulmonx Corp
$1.17
-0.05 (-4.10%)
At close · Jul 24
Market Cap
$49.42M
Shares
42.24M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$90.5M
+8%
FY2025
Net Income
-$54M
+4.2%
FY2025
Gross Margin
74.19%
+0.2pp
FY2025
Operating Margin
-59.3%
+9.6pp
FY2025
Diluted EPS
-$1.33
+7.6%
FY2025
Operating Cash Flow
-$32.38M
-2.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| $90M – $92M | $88.55M | $90.5MG | $83.79M | $68.68M | $53.66M | $48.42M | $32.73M | $32.6M | $20M | |
| — | $21.7M | $23.36M | $21.79M | $17.92M | $13.8M | $12.79M | $11.53M | $10.18M | $7.72M | |
| — | $66.84M | $67.14M | $62M | $50.75M | $39.87M | $35.63M | $21.2M | $22.41M | $12.29M | |
| — | — | 74.19% | 74% | 73.9% | 74.29% | 73.59% | 64.77% | 68.77% | 61.42% | |
| — | $19.63M | $19.49M | $17.57M | $18.08M | $15.4M | $13.06M | $7.46M | $6.05M | $6.99M | |
| — | $99.26M | $101.31M | $102.14M | $94.61M | $83.11M | $69.87M | $46.07M | $34.2M | $20.35M | |
| — | — | — | $100K | $100K | $100K | $100K | $100K | $100K | $100K | |
| — | $118.9M | $120.8M | $119.71M | $112.69M | $98.5M | $82.93M | $53.53M | $40.25M | $27.34M | |
| — | -$52.06M | -$53.66M | -$57.7M | -$61.94M | -$58.64M | -$47.3M | -$32.33M | -$17.84M | -$15.05M | |
| — | — | -59.3% | -68.87% | -90.19% | -109.27% | -97.7% | -98.77% | -54.73% | -75.24% | |
| — | $3.35M | $3.16M | $3.51M | $3.23M | $1.07M | $829K | $3.18M | $2.32M | $2.52M | |
| — | $2.14M | $2.65M | $5.06M | $5.57M | $1.53M | $400K | $213K | $432K | $21K | |
| — | $700K | $790K | $256K | -$673K | -$396K | -$585K | $3.28M | -$617K | -$916K | |
| — | -$52.57M | -$53.38M | -$55.89M | -$60.27M | -$58.57M | -$48.32M | -$32.02M | -$20.34M | -$18.47M | |
| — | $640K | $626K | $500K | $571K | $353K | $343K | $213K | $363K | $12K | |
| — | -$53.21M | -$54M | -$56.39M | -$60.84M | -$58.92M | -$48.66M | -$32.23M | -$20.7M | -$18.48M | |
| — | — | -59.67% | -67.3% | -88.6% | -109.8% | -100.51% | -98.47% | -63.52% | -92.38% | |
| — | -$53.24M | -$53.76M | -$56.92M | -$59.78M | -$59.06M | -$48.63M | -$31.92M | -$20.66M | -$18.35M | |
| USD/shares | — | — | -$1.33 | -$1.44 | -$1.60 | -$1.59 | -$1.35 | -$3.16 | — | — |
| USD/shares | — | — | -$1.33 | -$1.44 | -$1.60 | -$1.59 | -$1.35 | -$3.16 | — | — |
| shares | — | — | 40.69M | 39.11M | 37.97M | 37.1M | 36.13M | 10.18M | 1.78M | 1.67M |
| shares | — | — | 40.69M | 39.11M | 37.97M | 37.1M | 36.13M | 10.18M | 1.78M | 1.67M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2023: $86K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.14×
EV/EBIT
—
Medical Devices median 21.03×
P/E (TTM)
—
Medical Devices median 27.62×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $57,023,000 | $56,465,000 | $45,917,000 | $32,487,000 | $24,991,000 | $16,189,000 | $10,704,000 | $563,000 |
| EMEA | $26,985,000 | $22,329,000 | $19,336,000 | $18,154,000 | $19,883,000 | $13,808,000 | $18,364,000 | $16,175,000 |
| Asia Pacific | $6,229,000 | $4,439,000 | $3,023,000 | $2,866,000 | $3,414,000 | $2,687,000 | $3,227,000 | $3,115,000 |
| Other International Geographical Areas | $260,000 | $556,000 | $399,000 | $155,000 | $128,000 | $49,000 | $300,000 | $151,000 |